Effective August 2, 2022, mdxhealth has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences. To help ensure a smooth transition for patients, continue to place orders for this test through the existing Exact Sciences portal until further notice. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the Oncotype DX GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the following press release. Questions? Email: gps@mdxhealth.com

Metastatic castration-resistant prostate cancer (mCRPC) refers to cancer that has spread (metastasized) beyond the prostate gland and for which hormone therapy is no longer effective in stopping or slowing the disease.

For patients with mCRPC, Exact Sciences offers the Oncotype DX AR-V7 Nucleus Detect® assay, a liquid biopsy blood test to help patients quickly and confidently determine whether they'll respond to AR-targeted therapies.

The only predictive and prognostic test for patients with mCRPC, the AR-V7 Nucleus Detect test:

  • accurately identifies patients who will not benefit from AR-targeted therapies,1-2
  • is predictive of improved overall survival with taxanes versus AR-targeted therapies,1-2
  • provides easy-to-interpret results (a positive or negative result).




1Scher et al. JAMA Oncol. 2016.

27Scher et al. JAMA Oncol. 2018.